# Dose Ranging and Dose Frequency of LIPO-102

> **NCT00918814** · PHASE2 · COMPLETED · sponsor: **Neothetics, Inc** · enrollment: 54 (actual)

## Conditions studied

- Subcutaneous Adipose Tissue Reduction

## Interventions

- **DRUG:** LIPO-102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00918814
- **Lead sponsor:** Neothetics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00918814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00918814, "Dose Ranging and Dose Frequency of LIPO-102". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00918814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*